Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.47 |
| ▸ | ATR | Q13535 | 13/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607385 | 0.90 | PIK3CA (0.45) | PIK3CAATRMTORPRKDCNAPEPLD | |
| SCHEMBL3596951 | 0.88 | ATR (0.53) | PIK3CAATRMTORPRKDCPDCD1 | |
| SCHEMBL3607287 | 0.88 | PIK3CA (0.45) | PIK3CAATRMTORPRKDC | |
| SCHEMBL13119567 | 0.87 | PIK3CA (0.49) | PIK3CAATR | |
| SCHEMBL3596640 | 0.87 | ATR (0.50) | PIK3CAATRMTORPRKDCNAPEPLD | |
| SCHEMBL3602059 | 0.87 | PIK3CA (0.44) | PIK3CAATRMTORPRKDC | |
| SCHEMBL3598933 | 0.85 | PIK3CA (0.47) | PIK3CAATRMTORPRKDCNAPEPLD | |
| SCHEMBL1025702 | 0.84 | PIK3CA (0.49) | PIK3CAATRPRKDCTDO2 | |
| SCHEMBL1029698 | 0.84 | PIK3CA (0.60) | PIK3CAATR | |
| SCHEMBL1027000 | 0.83 | PIK3CA (0.53) | PIK3CAATRTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | claimed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | claimed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | claimed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2144906-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | PIK3CA 1/4885ATR 957/4885MTOR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.